Progression-Free Survival Increased With Zanubrutinib in Leukemia

TUESDAY, Jan. 3, 2023 -- Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study...